JP2023059873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023059873A5 JP2023059873A5 JP2023012793A JP2023012793A JP2023059873A5 JP 2023059873 A5 JP2023059873 A5 JP 2023059873A5 JP 2023012793 A JP2023012793 A JP 2023012793A JP 2023012793 A JP2023012793 A JP 2023012793A JP 2023059873 A5 JP2023059873 A5 JP 2023059873A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically engineered
- seq
- amino acid
- chain variable
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 230000004807 localization Effects 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 3
- 230000014759 maintenance of location Effects 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- -1 CD3ζ Proteins 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000026647 proteasome localization Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025004349A JP2025065142A (ja) | 2016-11-22 | 2025-01-10 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425398P | 2016-11-22 | 2016-11-22 | |
| US62/425,398 | 2016-11-22 | ||
| US201762543696P | 2017-08-10 | 2017-08-10 | |
| US62/543,696 | 2017-08-10 | ||
| JP2019547605A JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| PCT/US2017/063048 WO2018098306A1 (en) | 2016-11-22 | 2017-11-22 | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547605A Division JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004349A Division JP2025065142A (ja) | 2016-11-22 | 2025-01-10 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023059873A JP2023059873A (ja) | 2023-04-27 |
| JP2023059873A5 true JP2023059873A5 (enExample) | 2023-06-14 |
Family
ID=62193475
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547605A Active JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| JP2023012793A Pending JP2023059873A (ja) | 2016-11-22 | 2023-01-31 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| JP2025004349A Pending JP2025065142A (ja) | 2016-11-22 | 2025-01-10 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547605A Active JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004349A Pending JP2025065142A (ja) | 2016-11-22 | 2025-01-10 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10550183B2 (enExample) |
| EP (1) | EP3545082A4 (enExample) |
| JP (3) | JP7778468B2 (enExample) |
| KR (2) | KR20190085528A (enExample) |
| CN (3) | CN110268049B (enExample) |
| AU (3) | AU2017363278B2 (enExample) |
| CA (1) | CA3043752A1 (enExample) |
| SG (2) | SG10201912387PA (enExample) |
| WO (1) | WO2018098306A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102497660B1 (ko) | 2014-01-31 | 2023-02-07 | 모놀리스 머티어리얼스 인코포레이티드 | 플라즈마 토치 설계 |
| KR102705340B1 (ko) | 2015-02-03 | 2024-09-09 | 모놀리스 머티어리얼스 인코포레이티드 | 카본 블랙 생성 시스템 |
| ES2926384T3 (es) | 2015-02-06 | 2022-10-25 | Nat Univ Singapore | Métodos para mejorar la eficacia de células inmunitarias terapéuticas |
| CA3032246C (en) | 2015-07-29 | 2023-12-12 | Monolith Materials, Inc. | Dc plasma torch electrical power design method and apparatus |
| EP3347306A4 (en) | 2015-09-09 | 2019-04-17 | Monolith Materials, Inc. | CIRCULAR SINGLE-LAYER GRAPH |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| SG10201912387PA (en) | 2016-11-22 | 2020-02-27 | Nat Univ Singapore | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
| SG11202000555UA (en) | 2017-06-21 | 2020-02-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| KR20200035304A (ko) | 2017-08-10 | 2020-04-02 | 싱가포르국립대학교 | T 세포 수용체-결핍 키메라 항원 수용체 t-세포 및 이의 사용 방법 |
| JP7584299B2 (ja) | 2018-05-23 | 2024-11-15 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現 |
| US12227776B2 (en) | 2018-06-13 | 2025-02-18 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| US10227576B1 (en) | 2018-06-13 | 2019-03-12 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| WO2020091869A1 (en) * | 2018-10-31 | 2020-05-07 | Nantkwest, Inc. | Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| AU2019378039A1 (en) * | 2018-11-14 | 2021-05-27 | Medisix Therapeutics Pte Ltd. | Two-gene vectors for generating CAR-T cells and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| SG11202112382WA (en) | 2019-05-07 | 2021-12-30 | Gracell Biotechnologies Shanghai Co Ltd | Engineered immune cell targeting bcma and use thereof |
| GB201914611D0 (en) * | 2019-10-09 | 2019-11-20 | Autolus Ltd | Engineered immune cell |
| WO2021072250A1 (en) * | 2019-10-11 | 2021-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant polypeptides for regulatable cellular localization |
| US20230009232A1 (en) * | 2019-11-20 | 2023-01-12 | Cartherics Pty. Ltd. | Method for providing immune cells with enhanced function |
| KR20220137882A (ko) * | 2019-12-05 | 2022-10-12 | 바이셀릭스, 인크. | 보편적 세포 요법을 위한 면역 회피 기작의 조절제 |
| US20230019849A1 (en) * | 2019-12-09 | 2023-01-19 | St. Jude Children's Research Hospital, Inc. | Method for Preparing CD7-Negative, CD3-Positive T Cells |
| US12312407B2 (en) * | 2020-01-30 | 2025-05-27 | St Phi Therapeutics Co., Ltd. | Universal T cells and the method of use thereof |
| CN112300282A (zh) * | 2020-11-03 | 2021-02-02 | 南京北恒生物科技有限公司 | 靶向cd7的人源化抗体及其用途 |
| CN114525259B (zh) * | 2020-11-03 | 2025-02-14 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
| AU2021377699A1 (en) | 2020-11-13 | 2023-06-15 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| CN114525306B (zh) * | 2020-11-23 | 2025-01-28 | 博生吉医药科技(苏州)有限公司 | 一种cd7-car-t细胞的制备方法及应用 |
| US20240269304A1 (en) | 2020-11-24 | 2024-08-15 | Novartis Ag | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN115947852A (zh) * | 2021-01-12 | 2023-04-11 | 上海雅科生物科技有限公司 | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 |
| JP2024505955A (ja) * | 2021-02-03 | 2024-02-08 | バイオヘン セラピューティクス リミテッド | 新型キメラ抗原受容体及びその使用 |
| CN115044617B (zh) * | 2021-03-08 | 2024-08-13 | 河北森朗生物科技有限公司 | Car t细胞的制备方法、car t细胞及其应用 |
| CN112980800A (zh) * | 2021-03-08 | 2021-06-18 | 河北森朗生物科技有限公司 | Car-t细胞、其构建方法及其应用 |
| CN112662631B (zh) * | 2021-03-16 | 2021-06-29 | 合源生物科技(天津)有限公司 | 一种car-t细胞灌流培养方法 |
| CN117545492A (zh) | 2021-04-22 | 2024-02-09 | 贝勒医学院 | 工程改造具有减少的自相残杀活性的免疫细胞的方法 |
| US20250222026A1 (en) * | 2021-06-08 | 2025-07-10 | Beijing Meikang Geno-Immune Biotechnology Co., Ltd. | Cd7-based humanized chimeric antigen receptor and use thereof |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250161358A1 (en) * | 2022-02-17 | 2025-05-22 | Utc Therapeutics (Shanghai) Co., Ltd. | Modified immune effector cells and uses thereof |
| CN114560943B (zh) * | 2022-02-28 | 2022-12-16 | 先进生物(苏州)有限公司 | Cd7-car-t细胞及其制备方法和应用 |
| EP4501953A1 (en) * | 2022-03-29 | 2025-02-05 | Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences | Antibody that specifically binds to cd7 and use thereof in preparing chimeric antigen receptor |
| CN117004603A (zh) * | 2022-04-28 | 2023-11-07 | 南京北恒生物科技有限公司 | 一种cd7基因被敲除的工程化免疫细胞及其用途 |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| KR20250011947A (ko) | 2022-05-20 | 2025-01-22 | 노파르티스 아게 | 항체 약물 콘쥬게이트 |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| EP4559937A1 (en) * | 2023-11-24 | 2025-05-28 | Universitat de Barcelona | Cd7 targeting moieties for the treatment of cd7 positive cancer |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| WO1999014353A2 (en) | 1997-09-19 | 1999-03-25 | Dana-Farber Cancer Institute, Inc. | Intrabody-mediated control of immune reactions |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| AU2002361390A1 (en) * | 2001-12-14 | 2003-06-30 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| AU2005299353A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| CA2625998C (en) | 2005-10-06 | 2015-12-01 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| PL2132229T3 (pl) | 2007-03-01 | 2016-12-30 | Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka | |
| PL2185574T3 (pl) | 2007-09-07 | 2013-09-30 | Agensys Inc | Przeciwciała i powiązane cząsteczki, które wiążą się do białek 24P4C12 |
| MX2010007935A (es) | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| US8580714B2 (en) | 2009-10-14 | 2013-11-12 | Janssen Biotech, Inc. | Methods of affinity maturing antibodies |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2863799C (en) | 2012-02-22 | 2020-09-01 | Matthew J. FRIGAULT | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| FI3597749T3 (fi) | 2012-05-25 | 2023-10-09 | Univ California | Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten |
| ES2824024T3 (es) | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093831A2 (en) * | 2012-12-14 | 2014-06-19 | Thomson Reuters (Markets) Llc | Dynamic function builder |
| KR101521224B1 (ko) * | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
| SG10201700916SA (en) | 2012-12-27 | 2017-03-30 | Aduro Biotech Inc | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| WO2014124143A1 (en) | 2013-02-06 | 2014-08-14 | Anthrogenesis Corporation | Modified t lymphocytes having improved specificity |
| KR20210108497A (ko) | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| RS65484B1 (sr) | 2013-05-13 | 2024-05-31 | Cellectis | Cd19 specifični himerni antigenski receptor i njegove primene |
| DK3004337T3 (da) | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
| WO2015058018A1 (en) | 2013-10-17 | 2015-04-23 | National University Of Singapore | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors |
| WO2015075468A1 (en) | 2013-11-21 | 2015-05-28 | Ucl Business Plc | Cell |
| JP6673838B2 (ja) | 2014-02-14 | 2020-04-01 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞 |
| ES2740903T3 (es) | 2014-03-19 | 2020-02-07 | Cellectis | Receptores antigénicos quiméricos específicos de CD123 para inmunoterapia del cáncer |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| MX2017000646A (es) | 2014-07-15 | 2017-04-27 | Juno Therapeutics Inc | Celulas geneticamente modificadas para terapia celular adoptiva. |
| AU2015330017A1 (en) | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| ES2926384T3 (es) | 2015-02-06 | 2022-10-25 | Nat Univ Singapore | Métodos para mejorar la eficacia de células inmunitarias terapéuticas |
| EP3261651B1 (en) * | 2015-02-27 | 2022-05-04 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| CA2976684C (en) | 2015-03-02 | 2024-03-05 | Innovative Cellular Therapeutics CO., LTD. | Reducing immune tolerance induced by pd-l1 |
| GB201507104D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| GB2557123B (en) | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US11390658B2 (en) * | 2016-06-06 | 2022-07-19 | St. Jude Children's Research Hospital | Anti-CD7 chimeric antigen receptor and method of use thereof |
| CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
| US12350349B2 (en) * | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| SG10201912387PA (en) | 2016-11-22 | 2020-02-27 | Nat Univ Singapore | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
| KR20200035304A (ko) | 2017-08-10 | 2020-04-02 | 싱가포르국립대학교 | T 세포 수용체-결핍 키메라 항원 수용체 t-세포 및 이의 사용 방법 |
| AU2019378039A1 (en) | 2018-11-14 | 2021-05-27 | Medisix Therapeutics Pte Ltd. | Two-gene vectors for generating CAR-T cells and uses thereof |
-
2017
- 2017-11-22 SG SG10201912387PA patent/SG10201912387PA/en unknown
- 2017-11-22 EP EP17874643.4A patent/EP3545082A4/en active Pending
- 2017-11-22 CA CA3043752A patent/CA3043752A1/en active Pending
- 2017-11-22 AU AU2017363278A patent/AU2017363278B2/en active Active
- 2017-11-22 CN CN201780073071.6A patent/CN110268049B/zh active Active
- 2017-11-22 CN CN202410674086.XA patent/CN118562882B/zh active Active
- 2017-11-22 WO PCT/US2017/063048 patent/WO2018098306A1/en not_active Ceased
- 2017-11-22 KR KR1020197016703A patent/KR20190085528A/ko not_active Ceased
- 2017-11-22 KR KR1020247020607A patent/KR102889007B1/ko active Active
- 2017-11-22 US US15/821,170 patent/US10550183B2/en active Active
- 2017-11-22 CN CN202410674061.XA patent/CN118581046A/zh active Pending
- 2017-11-22 JP JP2019547605A patent/JP7778468B2/ja active Active
- 2017-11-22 SG SG11201903830TA patent/SG11201903830TA/en unknown
- 2017-11-22 US US15/821,153 patent/US11440958B2/en active Active
-
2022
- 2022-07-14 US US17/865,292 patent/US11945865B2/en active Active
- 2022-11-10 AU AU2022268355A patent/AU2022268355B2/en active Active
-
2023
- 2023-01-31 JP JP2023012793A patent/JP2023059873A/ja active Pending
-
2024
- 2024-02-21 US US18/583,551 patent/US20240182567A1/en active Pending
-
2025
- 2025-01-10 JP JP2025004349A patent/JP2025065142A/ja active Pending
- 2025-07-04 AU AU2025205147A patent/AU2025205147B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023059873A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| JP2021106605A5 (enExample) | ||
| JP2021177771A5 (enExample) | ||
| US10808019B2 (en) | Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligands | |
| JP7746323B2 (ja) | Ｐｄ－１及び４－１ｂｂの融合タンパク質 | |
| JP2021094037A5 (enExample) | ||
| JP2020517295A5 (enExample) | ||
| JP2023071729A5 (enExample) | ||
| JP2022109953A5 (enExample) | ||
| JP2020512005A5 (enExample) | ||
| JP2020114264A5 (enExample) | ||
| JP2019527557A5 (enExample) | ||
| JP2018525006A5 (enExample) | ||
| JP2019512222A5 (enExample) | ||
| JP2020511136A5 (enExample) | ||
| AU2018277301B2 (en) | Heterodimerizing Ig domains | |
| JP2018525033A5 (enExample) | ||
| JP2019525771A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| JP2021500881A5 (enExample) | ||
| FI3710067T3 (fi) | Polypeptidejä sisältävä d-domeeni ja niiden käyttötarkoitukset | |
| JP2017519502A5 (enExample) | ||
| JP2019532668A5 (enExample) | ||
| JP2017518071A5 (enExample) |